483 related articles for article (PubMed ID: 31548259)
1. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
2. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
3. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
4. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition.
Dutoit V; Guillaume P; Romero P; Cerottini JC; Valmori D
Cancer Immun; 2002 Jul; 2():7. PubMed ID: 12747752
[TBL] [Abstract][Full Text] [Related]
6. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
Robbins PF; Li YF; El-Gamil M; Zhao Y; Wargo JA; Zheng Z; Xu H; Morgan RA; Feldman SA; Johnson LA; Bennett AD; Dunn SM; Mahon TM; Jakobsen BK; Rosenberg SA
J Immunol; 2008 May; 180(9):6116-31. PubMed ID: 18424733
[TBL] [Abstract][Full Text] [Related]
7. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
8. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
9. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
10. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
[TBL] [Abstract][Full Text] [Related]
11. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
12. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L; Ferber M; Touvrey C; Devevre E; Zoete V; Leimgruber A; Romero P; Michielin O; Lévy F; Speiser DE
J Immunol; 2007 Dec; 179(11):7635-45. PubMed ID: 18025209
[TBL] [Abstract][Full Text] [Related]
13. Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.
Audehm S; Glaser M; Pecoraro M; Bräunlein E; Mall S; Klar R; Effenberger M; Albers J; Bianchi HO; Peper J; Yusufi N; Busch DH; Stevanović S; Mann M; Antes I; Krackhardt AM
Front Immunol; 2019; 10():1485. PubMed ID: 31316521
[TBL] [Abstract][Full Text] [Related]
14. Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains.
Harris DT; Hager MV; Smith SN; Cai Q; Stone JD; Kruger P; Lever M; Dushek O; Schmitt TM; Greenberg PD; Kranz DM
J Immunol; 2018 Feb; 200(3):1088-1100. PubMed ID: 29288199
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy.
Soon CF; Zhang S; Suneetha PV; Antunes DA; Manns MP; Raha S; Schultze-Florey C; Prinz I; Wedemeyer H; Sällberg Chen M; Cornberg M
Front Immunol; 2019; 10():2076. PubMed ID: 31552033
[TBL] [Abstract][Full Text] [Related]
17. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells.
Tan MP; Gerry AB; Brewer JE; Melchiori L; Bridgeman JS; Bennett AD; Pumphrey NJ; Jakobsen BK; Price DA; Ladell K; Sewell AK
Clin Exp Immunol; 2015 May; 180(2):255-70. PubMed ID: 25496365
[TBL] [Abstract][Full Text] [Related]
18. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
19. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Parkhurst MR; Joo J; Riley JP; Yu Z; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2009 Jan; 15(1):169-80. PubMed ID: 19118044
[TBL] [Abstract][Full Text] [Related]
20. Human leucocyte antigen class I-redirected anti-tumour CD4
Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]